Analysts Offer Predictions for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Brookline Capital Management raised their Q1 2025 earnings per share estimates for CervoMed in a note issued to investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post earnings per share of ($0.47) for the quarter, up from their prior estimate of ($0.48). Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

CRVO has been the topic of several other reports. HC Wainwright cut CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Roth Mkm raised their target price on CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a research note on Wednesday, December 11th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of CervoMed in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

CervoMed Price Performance

NASDAQ CRVO opened at $14.29 on Thursday. The stock has a market capitalization of $88.17 million, a PE ratio of -7.04 and a beta of 1.84. CervoMed has a 1 year low of $1.80 and a 1 year high of $25.92. The business’s 50-day moving average is $3.30 and its 200 day moving average is $7.87.

Institutional Trading of CervoMed

Several institutional investors and hedge funds have recently bought and sold shares of CRVO. Woodline Partners LP purchased a new position in shares of CervoMed during the fourth quarter valued at approximately $175,000. Perigon Wealth Management LLC purchased a new position in shares of CervoMed during the fourth quarter valued at approximately $147,000. State Street Corp lifted its holdings in shares of CervoMed by 28.1% during the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after purchasing an additional 22,104 shares during the last quarter. Finally, Cornerstone Wealth Management LLC purchased a new position in shares of CervoMed during the fourth quarter valued at approximately $48,000. 25.15% of the stock is currently owned by hedge funds and other institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.